3-[(5-bromo-2-chloropyrimidin-4-yl)-cyclopentylamino]-N-propan-2-ylpropanamide | 1001346-57-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-[(5-bromo-2-chloropyrimidin-4-yl)-cyclopentylamino]-N-propan-2-ylpropanamide
• CAS: 1001346-57-1
• 化学式: C₁₅H₂₂BrClN₄O
• 分子量: 389.723
• InChiKey: PWNJCJQVBVRUPE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  58.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-[(5-bromo-2-chloropyrimidin-4-yl)-cyclopentylamino]-N-propan-2-ylpropanamide 在 tris-(dibenzylideneacetone)dipalladium(0) 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.5h， 以55%的产率得到2-Chloro-9-cyclopentyl-5-propan-2-yl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one
  参考文献：
  名称：

  A novel approach to functionalised 5,7,8,9-tetrahydropyrimido[4,5-b][1,4]diazepin-6-ones using intramolecular palladium-catalysed amidation

  摘要：

  The development of a novel palladium-catalysed amidation approach towards 5,7,8,9-tetrahydropyrimido[4,5-b][1,4]diazepin-6-one templates is highlighted. The route proceeds through the reaction of an amino amide, generated by 1,4-addition of an amine to an acrylamide, with 5-bromo-2,4-dichloropyrimidine and final palladium-catalysed cyclisation to provide the functionalised scaffold in up to 60% isolated yield over three steps. The route offers efficiency advantages over the previously reported nitro-reduction cyclisation approach to these molecules. It also provides alternative means to introduce bulky alkyl substituents at the amide nitrogen. The application of this route in the synthesis of a variety of analogues is described. (C) 2012 Published by Elsevier Ltd.

  DOI：

  10.1016/j.tetlet.2012.03.125
• 作为产物：
  描述：

  N-异丙基丙烯酰胺 在 三乙胺 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 0.5h， 生成 3-[(5-bromo-2-chloropyrimidin-4-yl)-cyclopentylamino]-N-propan-2-ylpropanamide
  参考文献：
  名称：

  A novel approach to functionalised 5,7,8,9-tetrahydropyrimido[4,5-b][1,4]diazepin-6-ones using intramolecular palladium-catalysed amidation

  摘要：

  The development of a novel palladium-catalysed amidation approach towards 5,7,8,9-tetrahydropyrimido[4,5-b][1,4]diazepin-6-one templates is highlighted. The route proceeds through the reaction of an amino amide, generated by 1,4-addition of an amine to an acrylamide, with 5-bromo-2,4-dichloropyrimidine and final palladium-catalysed cyclisation to provide the functionalised scaffold in up to 60% isolated yield over three steps. The route offers efficiency advantages over the previously reported nitro-reduction cyclisation approach to these molecules. It also provides alternative means to introduce bulky alkyl substituents at the amide nitrogen. The application of this route in the synthesis of a variety of analogues is described. (C) 2012 Published by Elsevier Ltd.

  DOI：

  10.1016/j.tetlet.2012.03.125

文献信息

• NOVEL COMPOUNDS
  申请人：HALSALL Christopher Thomas

  公开号：US20080009482A1

  公开（公告）日：2008-01-10

  There is provided a compound of formula (I): processes for the manufacture thereof, pharmaceutical compositions thereof and uses in therapy.

  提供了一个化合物的化学式(I)： 其制备方法，药物组合物以及在治疗中的用途。
• FUSED PYRIMIDO COMPOUNDS
  申请人：AstraZeneca AB

  公开号：EP2046793A2

  公开（公告）日：2009-04-15
• US7709471B2
  申请人：——

  公开号：US7709471B2

  公开（公告）日：2010-05-04
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：ASTRAZENECA AB

  公开号：WO2008003958A2

  公开（公告）日：2008-01-10

  [EN] There is provided a compound of formula (I):processes for the manufacure thereof, pharmaceutical compoitions thereof and uses in therapy.
  [FR] L'invention concerne un composé représenté par la formule (I), des procédés de fabrication de ce composé, des compositions pharmaceutiques de ce composé et les utilisations thérapeutiques de ce composé.